The Neulasta FIRST STEP™ Program
The Neulasta FIRST STEP™ Program provides financial support to all eligible patients with commercial insurance and a Neulasta® co-insurance or co-payment requirement.
Enrollment:
To confirm your eligibility and enroll in the program, please call the hotline at 1-800-272-9376 or click here to access the Neulasta FIRST STEP™ website
Assistance From Independent Nonprofit Co-pay Foundations
Patients who are commercially and government insured (including Medicare), but need financial assistance, can be referred to independent nonprofit co-pay foundations. Amgen makes donations to these foundations that, in turn, help qualifying insured patients with out-of-pocket costs, including co-payments and premiums, to cover the medicines they need.
Amgen Assist™ can help patients identify which co-pay foundations they may be qualified for, and provide referrals for these foundations. However, Amgen Assist™ cannot guarantee that a patient will receive assistance since these co-pay foundations are independent and not affiliated with Amgen. Each foundation has its own eligibility criteria which includes an evaluation of individual’s financial, medical, and insurance status.
For more information about co-pay support or referral to an independent co-pay foundation, call one of our coverage and reimbursement services specialists at 1-800-272-9376.
Neulasta® Indication
Neulasta® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
Important Product Safety Information
SPLENIC RUPTURE, INCLUDING FATAL CASES, HAS BEEN REPORTED. IF PATIENTS REPORT LEFT UPPER ABDOMINAL AND/OR SHOULDER TIP PAIN, THEY SHOULD BE EVALUATED FOR AN ENLARGED SPLEEN OR SPLENIC RUPTURE.
Acute respiratory distress syndrome (ARDS) has been reported. Evaluate patients who develop fever, lung infiltrates, or respiratory distress for ARDS. If patient is diagnosed with ARDS, discontinue and/or withhold Neulasta® until resolution.
Allergic reactions to Neulasta®, manifesting as anaphylaxis, angioedema, or urticaria, have been reported. The majority of these reactions occurred upon initial exposure. However, in rare cases, allergic reactions, including anaphylaxis, recurred within days after discontinuing anti-allergic treatment.
Severe sickle cell crises have been associated with the use of Neulasta® in patients with sickle cell disorders. Only physicians qualified by specialized training or experience in the treatment of patients with sickle cell disorders should prescribe Neulasta® for such patients.
In clinical trials involving Neulasta®, bone pain was the most frequently reported adverse event.
